Dec 18, 2007 by Brian Orelli, PhDBristol-Myers' Sleeker ImageA private equity firm buys its medical-imaging division.
Dec 17, 2007 by Brian Orelli, PhDBarr Labs' Legal Tables TurnedThe pharmaceutical sues over patent infringement.
Dec 17, 2007 by Brian Orelli, PhDA Range of Changes for Stent MakersThe FDA is about to make it harder for drug-eluting stents to win its approval.
Dec 14, 2007 by Brian Orelli, PhDPanel Kills Merck's Hope of OTC StatusFDA advisory panel isn't convinced that MEVACOR deserves over-the-counter status.
Dec 14, 2007 by Brian Orelli, PhDAn Overnight Three-BaggerRigel triples overnight, but was it justified?
Dec 13, 2007 by Brian Orelli, PhDMerck's Vaccination WoesMerck recalls 1.2 million doses of a children's vaccine.
Dec 12, 2007 by Brian Orelli, PhDWhat's Merck Doing?Glad you asked. The drug company briefed investors on its pipeline yesterday.
Dec 12, 2007 by Brian Orelli, PhDCongress Calls Out Merck and Schering-PloughThe House of Representatives wants to know what's taking so long to release trial data.
Dec 11, 2007 by Brian Orelli, PhDMedicare Whacks Oncology DrugsIt reduces the reimbursement rate for two drugs for lymphoma.
Dec 11, 2007 by Brian Orelli, PhDMucous Migrates EastReckitt Benckiser purchases Adams Respiratory Therapeutics for $2.3 billion.
Dec 11, 2007 by Brian Orelli, PhDOncology Duo Takes a GambleMedarex and BMS plan to submit less-than-stellar data to the FDA.
Dec 7, 2007 by Brian Orelli, PhDAmylin's Temporarily Worthless Label ExpansionAmylin releases label expansion data that won't be useful for a few years.
Dec 6, 2007 by Brian Orelli, PhDAn Unlikely Chat With Your DoctorJ&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
Dec 5, 2007 by Brian Orelli, PhDMerck Stays ConservativeMerck sets the bar low with its 2008 guidance.
Dec 5, 2007 by Brian Orelli, PhDEarly Bird Gets the MS WormTeva's COPAXONE performs well in a label-expanding trial.
Dec 4, 2007 by Brian Orelli, PhDAn Early Gift to DrugmakersDrugmakers could be allowed to market for drugs' off-label indications.
Dec 3, 2007 by Brian Orelli, PhDMore Heartburn From J&J's NatrecorThe company takes a $440 million writedown as the heart drug continues to falter.
Dec 3, 2007 by Brian Orelli, PhDNebivolol's Almost Approvable LetterForest and Mylan get an approvable letter for Nebivolol.
Nov 30, 2007 by Brian Orelli, PhDClinical Trial Failures Don't Bother These CompaniesContract research organizations succeed even when drugs fail, and more work may be coming their way.
